PE20130817A1 - Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos - Google Patents
Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismosInfo
- Publication number
- PE20130817A1 PE20130817A1 PE2013000253A PE2013000253A PE20130817A1 PE 20130817 A1 PE20130817 A1 PE 20130817A1 PE 2013000253 A PE2013000253 A PE 2013000253A PE 2013000253 A PE2013000253 A PE 2013000253A PE 20130817 A1 PE20130817 A1 PE 20130817A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- n3pglu
- beta amyloid
- peptide antibodies
- string
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO MONOCLONAL ALFA BETA ANTI-N3pGLu DISENADO POR INGENIERIA GENETICA Y UN FRAGMENTO DE UNION AL ANTIGENO DEL MISMO QUE COMPRENDE UNA REGION VARIABLE FORMADA POR SECUENCIAS DE AMINOACIDOS: a)CADENA LIGERA R1 (LCDR1) DE SEC ID N°3, SEC ID N°45; b) CADENA LIGERA R2 (LCDR2) DE SEC ID N°4, SEC ID N°35, c)CADENA LIGERA R3 (LCDR3) DE SEC ID N°5; d) CADENA PESADA R1(HCDR1) DE SEC ID N°6, SEC ID N°7, SEC ID N°40; e) CADENA PESADA R2(HCDR2) DE SEC ID N°8; f)CADENA PESADA R3(HCDR3) SECUENCIAS SELECCIONADAS DE SEC ID N°9, SEC ID N°10, SEC ID N°41, SEC ID N°46. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DEL ALZHEIMER.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37302610P | 2010-08-12 | 2010-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130817A1 true PE20130817A1 (es) | 2013-07-18 |
Family
ID=44543826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000253A PE20130817A1 (es) | 2010-08-12 | 2011-08-09 | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US8679498B2 (es) |
| EP (3) | EP3339323B1 (es) |
| JP (2) | JP5980207B2 (es) |
| KR (1) | KR101498833B1 (es) |
| CN (2) | CN103068848B (es) |
| AU (1) | AU2011289629B2 (es) |
| BR (1) | BR112013004056B8 (es) |
| CA (1) | CA2805114C (es) |
| CL (1) | CL2013000390A1 (es) |
| CO (1) | CO6670526A2 (es) |
| CR (1) | CR20130016A (es) |
| CY (2) | CY1120144T1 (es) |
| DK (3) | DK2603523T3 (es) |
| DO (1) | DOP2013000029A (es) |
| EA (1) | EA023021B1 (es) |
| EC (1) | ECSP13012436A (es) |
| ES (3) | ES2764728T3 (es) |
| FI (1) | FIC20250038I1 (es) |
| GT (1) | GT201300036A (es) |
| HR (3) | HRP20160151T1 (es) |
| HU (2) | HUE028678T2 (es) |
| IL (2) | IL224030B (es) |
| LT (2) | LT3339323T (es) |
| MA (1) | MA34461B1 (es) |
| ME (3) | ME03032B (es) |
| MX (2) | MX342782B (es) |
| MY (2) | MY163521A (es) |
| NO (2) | NO3042917T3 (es) |
| NZ (2) | NZ606095A (es) |
| PE (1) | PE20130817A1 (es) |
| PH (1) | PH12013500277A1 (es) |
| PL (3) | PL2603523T3 (es) |
| PT (2) | PT3339323T (es) |
| RS (3) | RS57026B1 (es) |
| SG (2) | SG187586A1 (es) |
| SI (3) | SI3339323T1 (es) |
| UA (1) | UA107600C2 (es) |
| WO (1) | WO2012021469A1 (es) |
| ZA (1) | ZA201300437B (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| LT3339323T (lt) * | 2010-08-12 | 2020-02-10 | Eli Lilly And Company | Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| WO2015113169A1 (en) * | 2014-02-03 | 2015-08-06 | Cnj Holdings, Inc. | Humanized beta-amyloid binding molecules and uses thereof |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| WO2016005950A1 (en) * | 2014-07-10 | 2016-01-14 | Novartis Ag | Immune-stimulating monoclonal antibodies against human interleukin-2 |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| WO2016097305A1 (en) | 2014-12-19 | 2016-06-23 | Probiodrug Ag | Novel method for the detection of pglu-abeta peptides |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| ES2901133T3 (es) * | 2015-09-23 | 2022-03-21 | Regeneron Pharma | Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos |
| EA039865B1 (ru) | 2016-01-11 | 2022-03-22 | Универзитет Цюрих | Иммуностимулирующее гуманизированное моноклональное антитело против интерлейкина-2 человека и слитый белок |
| JOP20170004B1 (ar) * | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| AR107783A1 (es) * | 2016-03-15 | 2018-06-06 | Lilly Co Eli | Terapia de combinación |
| AR107774A1 (es) * | 2016-03-16 | 2018-05-30 | Lilly Co Eli | Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JP6949102B2 (ja) * | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | 併用療法 |
| CN109641052A (zh) * | 2016-08-18 | 2019-04-16 | 伊莱利利公司 | BACE-1抑制剂和抗-N3pGlu Aβ抗体的组合疗法 |
| AR110470A1 (es) * | 2016-10-21 | 2019-04-03 | Lilly Co Eli | Terapia de combinación para tratar la enfermedad de alzheimer |
| MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
| EP3532064B1 (en) | 2016-10-28 | 2020-07-29 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| CA3070446A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
| EP3672631B9 (en) | 2017-08-22 | 2023-06-28 | Biogen MA Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| SG11202005361RA (en) | 2017-12-14 | 2020-07-29 | H Lundbeck As | Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines |
| EP3728250A1 (en) | 2017-12-20 | 2020-10-28 | H. Lundbeck A/S | PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS |
| CN110366560B (zh) * | 2018-02-11 | 2023-07-28 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| JP2021516682A (ja) * | 2018-03-13 | 2021-07-08 | スミヴェット ビー．ブイ．Ｓｍｉｖｅｔ Ｂ．Ｖ． | 破傷風神経毒素に結合する単一ドメイン抗体 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| WO2020193644A1 (en) * | 2019-03-26 | 2020-10-01 | Janssen Pharmaceutica Nv | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
| AU2020368369A1 (en) | 2019-10-15 | 2022-05-12 | Eli Lilly And Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| KR20230016186A (ko) | 2020-05-26 | 2023-02-01 | 트루바인딩 아이엔씨. | 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법 |
| US20230250193A1 (en) * | 2020-06-17 | 2023-08-10 | Proviva Therapeutics (Hong Kong) Limited | Antibodies to fibroblast activation protein and b7h3 |
| US12435129B2 (en) | 2020-07-23 | 2025-10-07 | Othair Prothena Limited | Anti-Aβ antibodies |
| EP4222160A1 (en) * | 2020-10-02 | 2023-08-09 | Eli Lilly and Company | Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| IL312045A (en) | 2021-10-22 | 2024-06-01 | Lilly Co Eli | O-glcnacase (oga) inhibitor combination therapy |
| AR127484A1 (es) | 2021-10-29 | 2024-01-31 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
| CA3236547A1 (en) | 2021-10-29 | 2023-05-04 | Marcio Chedid | Compounds and methods targeting interleukin-34 |
| WO2023076971A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly Company | Compounds and methods targeting interleukin-34 |
| CN118475609A (zh) | 2021-10-29 | 2024-08-09 | 伊莱利利公司 | 靶向白细胞介素-34的化合物和方法 |
| EP4472679A1 (en) | 2022-02-03 | 2024-12-11 | Eli Lilly and Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
| AU2023309007A1 (en) * | 2022-07-21 | 2025-01-30 | Eli Lilly And Company | PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF |
| CN120731223A (zh) | 2022-12-22 | 2025-09-30 | 生物极公司 | 与AβpE3结合的抗体 |
| WO2025106313A1 (en) | 2023-11-14 | 2025-05-22 | Eli Lilly And Company | Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES |
| WO2025245381A1 (en) | 2024-05-23 | 2025-11-27 | The Trustrees Of Dartmouth College | Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| EP1911765A3 (en) | 2002-07-24 | 2008-04-23 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation |
| WO2005018424A2 (en) * | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| KR20090005410A (ko) * | 2004-02-23 | 2009-01-13 | 일라이 릴리 앤드 캄파니 | 항-Ａβ 항체 |
| MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| TWI551607B (zh) | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| EP2146746A4 (en) * | 2007-04-18 | 2011-03-23 | Janssen Alzheimer Immunotherap | PREVENTIVE AND TREATING ZEREBRALER AMYLOID ANGIOPATHY |
| CA2723995A1 (en) | 2008-06-12 | 2009-12-17 | Affiris Ag | Compounds for treating symptoms associated with parkinson's disease |
| US20110182809A1 (en) | 2008-07-09 | 2011-07-28 | University Of Zurich | Method of Promoting Neurogenesis |
| EP3338795A1 (en) * | 2008-07-21 | 2018-06-27 | Probiodrug AG | Diagnostic antibody assay |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| LT3339323T (lt) * | 2010-08-12 | 2020-02-10 | Eli Lilly And Company | Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas |
-
2011
- 2011-08-09 LT LTEP18150424.2T patent/LT3339323T/lt unknown
- 2011-08-09 DK DK11745672.3T patent/DK2603523T3/en active
- 2011-08-09 RS RS20180323A patent/RS57026B1/sr unknown
- 2011-08-09 PL PL11745672T patent/PL2603523T3/pl unknown
- 2011-08-09 ME MEP-2018-79A patent/ME03032B/me unknown
- 2011-08-09 PH PH1/2013/500277A patent/PH12013500277A1/en unknown
- 2011-08-09 EP EP18150424.2A patent/EP3339323B1/en active Active
- 2011-08-09 ME MEP-2019-356A patent/ME03661B/me unknown
- 2011-08-09 PL PL15196358T patent/PL3042917T3/pl unknown
- 2011-08-09 EP EP15196358.4A patent/EP3042917B1/en active Active
- 2011-08-09 MX MX2013001716A patent/MX342782B/es active IP Right Grant
- 2011-08-09 RS RS20160129A patent/RS54685B1/sr unknown
- 2011-08-09 PE PE2013000253A patent/PE20130817A1/es active IP Right Grant
- 2011-08-09 EA EA201270813A patent/EA023021B1/ru not_active IP Right Cessation
- 2011-08-09 NZ NZ606095A patent/NZ606095A/en unknown
- 2011-08-09 NO NO15196358A patent/NO3042917T3/no unknown
- 2011-08-09 PT PT181504242T patent/PT3339323T/pt unknown
- 2011-08-09 HR HRP20160151TT patent/HRP20160151T1/hr unknown
- 2011-08-09 KR KR1020137003412A patent/KR101498833B1/ko active Active
- 2011-08-09 DK DK18150424.2T patent/DK3339323T3/da active
- 2011-08-09 MY MYPI2013700226A patent/MY163521A/en unknown
- 2011-08-09 MA MA35653A patent/MA34461B1/fr unknown
- 2011-08-09 LT LTEP15196358.4T patent/LT3042917T/lt unknown
- 2011-08-09 US US13/810,895 patent/US8679498B2/en active Active
- 2011-08-09 PL PL18150424T patent/PL3339323T3/pl unknown
- 2011-08-09 JP JP2013524156A patent/JP5980207B2/ja active Active
- 2011-08-09 ME MEP-2016-28A patent/ME02352B/me unknown
- 2011-08-09 HU HUE11745672A patent/HUE028678T2/en unknown
- 2011-08-09 SI SI201131817T patent/SI3339323T1/sl unknown
- 2011-08-09 HU HUE15196358A patent/HUE037524T2/hu unknown
- 2011-08-09 WO PCT/US2011/046994 patent/WO2012021469A1/en not_active Ceased
- 2011-08-09 CN CN201180039876.1A patent/CN103068848B/zh active Active
- 2011-08-09 DK DK15196358.4T patent/DK3042917T3/en active
- 2011-08-09 BR BR112013004056A patent/BR112013004056B8/pt active IP Right Grant
- 2011-08-09 SI SI201130740T patent/SI2603523T1/sl unknown
- 2011-08-09 MY MYPI2016001651A patent/MY181969A/en unknown
- 2011-08-09 ES ES18150424T patent/ES2764728T3/es active Active
- 2011-08-09 SI SI201131449T patent/SI3042917T1/en unknown
- 2011-08-09 CA CA2805114A patent/CA2805114C/en active Active
- 2011-08-09 SG SG2013005210A patent/SG187586A1/en unknown
- 2011-08-09 SG SG10201509330XA patent/SG10201509330XA/en unknown
- 2011-08-09 EP EP11745672.3A patent/EP2603523B1/en active Active
- 2011-08-09 ES ES15196358.4T patent/ES2664128T3/es active Active
- 2011-08-09 CN CN201510613319.6A patent/CN105111308B/zh active Active
- 2011-08-09 AU AU2011289629A patent/AU2011289629B2/en active Active
- 2011-08-09 ES ES11745672.3T patent/ES2564252T3/es active Active
- 2011-08-09 NZ NZ626665A patent/NZ626665A/en unknown
- 2011-08-09 RS RS20191581A patent/RS59652B1/sr unknown
- 2011-08-09 PT PT151963584T patent/PT3042917T/pt unknown
- 2011-09-08 UA UAA201301508A patent/UA107600C2/ru unknown
-
2012
- 2012-12-31 IL IL224030A patent/IL224030B/en unknown
-
2013
- 2013-01-16 ZA ZA2013/00437A patent/ZA201300437B/en unknown
- 2013-01-16 CR CR20130016A patent/CR20130016A/es unknown
- 2013-02-05 DO DO2013000029A patent/DOP2013000029A/es unknown
- 2013-02-08 GT GT201300036A patent/GT201300036A/es unknown
- 2013-02-08 CL CL2013000390A patent/CL2013000390A1/es unknown
- 2013-02-08 EC ECSP13012436 patent/ECSP13012436A/es unknown
- 2013-02-12 CO CO13028596A patent/CO6670526A2/es unknown
- 2013-02-12 MX MX2016005533A patent/MX355268B/es unknown
- 2013-09-27 US US14/039,113 patent/US8961972B2/en active Active
-
2016
- 2016-04-22 JP JP2016086317A patent/JP6395755B2/ja active Active
-
2018
- 2018-04-18 HR HRP20180616TT patent/HRP20180616T1/hr unknown
- 2018-04-20 CY CY20181100420T patent/CY1120144T1/el unknown
-
2019
- 2019-12-12 HR HRP20192233TT patent/HRP20192233T1/hr unknown
-
2020
- 2020-01-07 CY CY20201100005T patent/CY1122458T1/el unknown
-
2021
- 2021-07-29 IL IL285226A patent/IL285226B2/en unknown
-
2025
- 2025-12-11 NO NO2025056C patent/NO2025056I1/no unknown
- 2025-12-18 FI FIC20250038C patent/FIC20250038I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| MX389805B (es) | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
| PE20081503A1 (es) | Miembros de union para il-6 | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| PE20091261A1 (es) | Anticuerpos anti-hepcidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |